![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/MOREPENLAB.png)
Share the post "Morepen Laboratories ‘s Q3 2024-25 Latest News: Revenue Grows by 1.85% YoY"
Highlights
🔹 The presented financial data is Consolidated to provide a comprehensive overview of the company performance. 🔹 Sales over the Year and quarter: The company experienced a substantial growth of 1.85 % in the past year, substantial increase in net sales/revenue by 3.44 %. 🔹 Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 31.1 %. Marginal increase in other income during this quarter, up by 7%. 🔹 Profit over the Year and quarter: Challenges in sustaining profitability for Morepen Laboratories Limited. Profit dropped by -16.57 % Year to Year, Morepen Laboratories Limited’s profitability dropped by -23.42 % Quarter to Quarter. 🔹 EPS over the Year and quarter: EPS declined by -22.22 % Year to Year. EPS decreased by -24.62 % in previous quarter. Analysis needed for shareholder value.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 444.554 Cr | Rs. 437.726 Cr | Rs. 452.781 Cr | + 3.44 % | + 1.85 % |
| Expenses | Rs. 393.99 Cr | Rs. 393.66 Cr | Rs. 416.64 Cr | + 5.84 % | + 5.75 % |
| Operating Profit | Rs. 50.56 Cr | Rs. 44.07 Cr | Rs. 36.14 Cr | -17.99 % | -28.52 % |
| OPM % | 11.37 % | 10.07 % | 7.98 % | -2.09 % | -3.39 % |
| Other Income | Rs. 4.071 Cr | Rs. 4.988 Cr | Rs. 5.337 Cr | + 7 % | + 31.1 % |
| Interest | Rs. 2.17 Cr | Rs. 1.18 Cr | Rs. 1.34 Cr | + 13.56 % | -38.25 % |
| Depreciation | Rs. 8.45 Cr | Rs. 1.86 Cr | Rs. 4.93 Cr | + 165.05 % | -41.66 % |
| Profit before tax | Rs. 44.01 Cr | Rs. 46.02 Cr | Rs. 35.21 Cr | -23.49 % | -20 % |
| Tax % | 27.33 % | 24.28 % | 24.19 % | -0.09 % | -3.14 % |
| Net Profit | Rs. 31.99 Cr | Rs. 34.85 Cr | Rs. 26.69 Cr | -23.41 % | -16.57 % |
| EPS in Rs | Rs. 0.63 | Rs. 0.65 | Rs. 0.49 | -24.62 % | -22.22 % |
Today, we’re looking at Morepen Laboratories Limited’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a robust year-over-year sales growth of 1.85 %. However, it did see a marginal increase of 3.44 % from the previous quarter. Expenses ticked up slightly by 5.84 % quarter-on-quarter, aligning with the annual rise of 5.75 %. Operating profit, while down -28.52 % compared to last year, faced a quarter-on-quarter dip of -17.99 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -3.39 %, but a shrinkage of -2.09 % sequentially. Other income rose by 7 % compared to the last quarter, despite an annual growth of 31.1 %. Interest expenses surged remarkably by 13.56 % from the previous quarter, yet the year-over-year decrease remains at a moderate -38.25 %. Depreciation costs climbed by 165.05 % quarter-on-quarter, yet on an annual scale, they experienced a reduction of -41.66 %. Profit before tax declined annually by -20 % but saw a reduction from the preceding quarter by -23.49 %.
Tax expenses as a percentage of profits decreased slightly by -3.14 % compared to last year, with a more notable quarter-on-quarter decrease of -0.09 %. Net profit fell by -16.57 % year-on-year but witnessed a -23.41 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual downturn of -22.22 % but a quarterly fall of -24.62 %. In summary, Morepen Laboratories Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 444.554 Cr | Rs. 437.726 Cr | Rs. 452.781 Cr | + 3.44 % | + 1.85 % |
| Expenses | Rs. 393.99 Cr | Rs. 393.66 Cr | Rs. 416.64 Cr | + 5.84 % | + 5.75 % |
| Operating Profit | Rs. 50.56 Cr | Rs. 44.07 Cr | Rs. 36.14 Cr | -17.99 % | -28.52 % |
| Net Profit | Rs. 31.99 Cr | Rs. 34.85 Cr | Rs. 26.69 Cr | -23.41 % | -16.57 % |
| EPS in Rs | Rs. 0.63 | Rs. 0.65 | Rs. 0.49 | -24.62 % | -22.22 % |
In reviewing Morepen Laboratories Limited’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 1.85 % year-on-year growth, however, there was a minor increase of 3.44 % from the previous quarter. Expenses rose by 5.75 % compared to the previous year, with a 5.84 % increase quarter-on-quarter. Operating Profit dropped by -28.52 % annually, and saw a -17.99 % decrease from the last quarter.
Net Profit showed yearly decrease of -16.57 %, and experienced a -23.41 % decrease from the previous quarter. Earnings Per Share (EPS) fell by -22.22 % annually, however dipped by -24.62 % compared to the last quarter. In essence, while Morepen Laboratories Limited exhibits strong annual growth indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/ASHIANA.png)